Search results
Showing 346 to 360 of 539 results for syndrome
antiplatelet therapy for people aged 75 and over with an acute coronary syndrome, who are having percutaneous coronary intervention...
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]
Discontinued Reference number: GID-TA10897
This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.
This guidance has been updated and replaced by NICE HealthTech guidance 623.
This quality standard covers diagnosing and managing renal cell carcinoma in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS215Show all sections
Sections for QS215
- Quality statements
- Quality statement 1: Suspected cancer pathway referral
- Quality statement 2: Renal biopsy for small renal lesions
- Quality statement 3: Clinical nurse specialist
- Quality statement 4: Surgery with curative intent
- Quality statement 5: Follow-up imaging
- Quality statement 6: Uro–oncology multidisciplinary team
- About this quality standard
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)
Evidence-based recommendations on rituximab for treating relapsed or refractory chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.
Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.
and effective as first-line therapy in the treatment of [Irritable bowel syndrome] (IBS), and which is the most effective and safe...
This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.
Open femoro–acetabular surgery for hip impingement syndrome (IPG403)
Interventional procedures, IPG403 - Issued: July 2011 --> We have moved interventional procedures guidance 403 to become HealthTech guidance 270. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Arthroscopic femoro–acetabular surgery for hip impingement syndrome (IPG408)
Interventional procedures, IPG408 - Issued: September 2011 --> We have moved interventional procedures guidance 408 to become HealthTech guidance 273. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Biographies for all current members of the diagnostics advisory committee.
This guideline covers recognising and managing antisocial behaviour and conduct disorders in children and young people aged under 19. It aims to improve care by identifying children and young people who are at risk and when interventions can prevent conduct disorders from developing. The guideline also makes recommendations on communication, to help professionals build relationships with children and young people and involve them in their own care.
Teduglutide for treating short bowel syndrome (terminated appraisal) (TA690)
This guidance has been updated and replaced by NICE technology appraisal guidance TA804.